Business
Ehave Expands into the Cannabis Industry -- CFN Media
Ehave Expands into the Cannabis Industry -- CFN Media.
About this update from Ehave Inc.
[{"type":"text","content":"\n\n SEATTLE, WA, Dec. 05, 2017 (GLOBE NEWSWIRE) -- \n CFN Media Group (\"CannabisFN\"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering the recent partnership between  Ehave Inc. (OTCQB: EHVVF) and MedReleaf Corp. (TSE: LEAF), one of Canada’s most prominent licensed producers. The two companies have joined together to introduce Ehave’s proven and effective patient management software platform to the medical marijuana industry in Canada. There are more than 200,000 registered patients in Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) program. These patients have been purchasing roughly 2,000 kilograms of dried marijuana and the same amount of cannabis oil each month to treat a wide range of symptoms. Deloitte analysts believe that the country’s cannabis industry will continue to grow to upwards of $22.6 billion over the coming years. Complex Processes Most people are familiar with the process of obtaining traditional medical treatments: You visit a doctor’s office, receive a consultation, and leave with a prescription. While medical cannabis is legal in Canada, registering as a patient and receiving good treatment is difficult. Patients must first consult with a healthcare professional to see if they qualify for medical cannabis (assuming that physician is comfortable prescribing it). Next, the healthcare professional must submit an authorization form to Health Canada to register the patient. And finally, the patients must choose a licensed producer of medical cannabis where they will receive mail order product on a regular basis. After the patient is enrolled, many healthcare professionals find it difficult to follow-up and ensure that the patient is on the right treatment plan. The medical cannabis industry doesn’t have the luxury of numerous clinical studies demonstrating the right dosing and delivery methods, which means that physicians must rely on their own expertise. The lack of standardization among licensed producers also means that results may vary. MedReleaf Agreement The upshot is that many companies are working on solutions to make this process a lot easier, including Ehave Inc. (OTCQB: EHVVF) and MedReleaf Corp. (TSE: LEAF), o...